Immitra Bio
Develops a scalable in-vivo genetic medicine platform aimed at advancing therapeutic delivery and development.
Overview
Immitra Bio is a Zürich-based biotechnology company building a scalable in-vivo genetic medicine platform. Its work targets the genetic medicines market, where companies seek delivery and development approaches that can support therapies inside the body. The company’s stated differentiator is scalability for in-vivo genetic medicine, positioning it as a platform developer rather than a single-asset biotech. Immitra Bio raised €3 million in pre-seed funding in July 2026 to scale its platform.
Funding History
Zürich-based Immitra Bio secures €2.58 million to scale its scalable in-vivo genetic medicine platform
Frequently Asked Questions
- How much funding does AI Funding track for Immitra Bio?
- AI Funding tracks €3M for Immitra Bio across 1 funding round in this database.
- Who are Immitra Bio's investors?
- Immitra Bio's investors include Backbone Ventures.
- What does Immitra Bio do?
- Immitra Bio is a Zürich-based biotechnology company building a scalable in-vivo genetic medicine platform. Its work targets the genetic medicines market, where companies seek delivery and development approaches that can support therapies inside the body. The company’s stated differentiator is scalability for in-vivo genetic medicine, positioning it as a platform developer rather than a single-asset biotech. Immitra Bio raised €3 million in pre-seed funding in July 2026 to scale its platform.
- Where is Immitra Bio headquartered?
- Immitra Bio is headquartered in Zürich, Switzerland.
Investors
Related Insights
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
Track 395+ AI funding rounds—investors, valuations, and deal sizes from pre-seed to IPO. Updated daily so you never miss a round.
An in-depth look at how AI-focused venture capital operates — from fund structure and deal sourcing to due diligence, portfolio management, and exit strategies in the AI era.